Evidence map›Paper›PMID 34856937›Full record

ArticleBMC infectious diseases2021

A Metabolomics approach for the diagnosis Of SecondAry InfeCtions in COVID-19 (MOSAIC): a study protocol.

Gordan McCreath, Phillip D Whitfield, Andrew J Roe, Malcolm J Watson, Malcolm A B Sim

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Monophasic Variant ofMicroorganisms · 2023
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Gordan McCreathInstitute of Infection, Immunity and Inflammation, Sir Graeme Davis Building, University Place, Glasgow, Scotland. gordan.mccreath@ggc.scot.nhs.uk.ORCID http://orcid.org/0000-0003-2156-7471
Phillip D WhitfieldGlasgow Polyomics, University of Glasgow, Garscube Campus, Glasgow, Scotland.
Andrew J RoeInstitute of Infection, Immunity and Inflammation, Sir Graeme Davis Building, University Place, Glasgow, Scotland.
Malcolm J WatsonSchool of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasglow, G12 8QQ, Scotland.
Malcolm A B SimSchool of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasglow, G12 8QQ, Scotland.
University of Glasgow · GBCentre for Inflammation Research · GBInstitute of Infection and Immunity · CA

Funding

Chief Scientist Office COV/GLA/20/08
6 · The paper itself

Abstract

backgroundCritically ill patients with COVID-19 are at an increased risk of developing secondary bacterial infections. These are both difficult to diagnose and are associated with an increased mortality. Metabolomics may aid clinicians in diagnosing secondary bacterial infections in COVID-19 through identification and quantification of disease specific biomarkers, with the aim of identifying underlying causative microorganisms and directing antimicrobial therapy.

methodsThis is a multi-centre prospective diagnostic observational study. Patients with COVID-19 will be recruited from critical care units in three Scottish hospitals. Three serial blood samples will be taken from patients, and an additional sample taken if a patient shows clinical or microbiological evidence of secondary infection. Samples will be analysed using LC-MS and subjected to bioinformatic processing and statistical analysis to explore the metabolite changes associated with bacterial infections in COVID-19 patients. Comparisons of the data sets will be made with standard microbiological and biochemical methods of diagnosing infection. DISCUSSION: Metabolomics analyses may provide additional strategies for identifying secondary infections, which might permit faster initiation of specific tailored antimicrobial therapy to critically ill patients with COVID-19.

Indexed as

CoinfectionCOVID-19HumansMetabolomicsMulticenter Studies as TopicObservational Studies as TopicProspective StudiesSARS-CoV-2COVID-19Critical careMetabolomicsSecondary infection

Identifiers

PMID34856937
PMCPMC8637512
OpenAlexW3216748095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.